文献速递血液净化与透析

NF-κB诱饵寡脱氧核苷酸涂层球囊导管治疗血液透析动静脉瘘狭窄的随机研究

NF-κB Decoy Oligodeoxynucleotide-Coated Balloon Catheter for Arteriovenous Fistula in Hemodialysis.
PubMed 文献 · Kidney Int Rep · 2018-10-01

本研究为前瞻性开放标签随机试验,纳入175例接受血液透析且吻合口区域静脉狭窄的患者,比较AMG0102(含NF-κB诱饵ODN的球囊导管)与PTA球囊导管的安全性和有效性。主要终点靶静脉狭窄部位一期通畅持续时间在AMG0102组有降低再狭窄风险趋势但无统计学显著性(分层log-rank P=0.250,HR 0.774,95%CI 0.500-1.198)。中位一期通畅时间AMG0102组245天,对照组172天;糖尿病并发症亚组中AMG0102组中位通畅时间延长108天(245天 vs 137天),但差异无统计学意义。不良事件发生率两组无差异。

要点

  • AMG0102涂层球囊未显著降低AVF狭窄再狭窄风险(P=0.250)。
  • AMG0102组中位一期通畅时间245天,对照组172天。
  • 糖尿病并发症亚组中AMG0102组中位通畅时间延长108天。

核心结论

  • AMG0102涂层球囊在降低AVF狭窄再狭窄风险方面未达到统计学显著性,需进一步改良以增强NF-κB诱饵ODN摄取和疗效。

研究设计与样本

  • 前瞻性开放标签随机研究,纳入175例年龄≥20岁、接受血液透析且吻合口区域静脉狭窄的患者,术后随访36周。

主要发现

  • AMG0102组再狭窄风险较低但无统计学意义(分层log-rank P=0.250,HR 0.774,95%CI 0.500-1.198)。
  • 中位一期通畅时间AMG0102组245天,对照组172天。
  • 糖尿病并发症亚组中AMG0102组HR 0.666(95%CI 0.366-1.212,P=0.183),中位通畅时间245天 vs 对照组137天,延长108天。
  • 术后36周内不良事件发生率两组无差异;AMG0102组3例患者发生4次器械失败,均未导致不良事件。

临床怎么用

  • 目前证据尚不支持常规使用NF-κB诱饵ODN涂层球囊预防AVF狭窄再狭窄,需进一步研究改良。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: New treatments to inhibit neointimal formation after percutaneous transluminal angioplasty (PTA) are needed for patients undergoing chronic hemodialysis (HD). We compared the efficacy and safety of AMG0102, a balloon catheter containing nuclear factor κB (NF-κB) decoy oligodeoxynucleotide (ODN) with the PTA balloon catheter (control group) for arteriovenous fistula (AVF) stenosis. METHODS: In total, 175 patients (age ≥20 years, undergoing HD, with venous stenosis at the anastomotic region) were registered in this prospective open-label, randomized study. Patients were followed postoperatively for 36 weeks. The duration of primary patency on the targeted venous stenosis site (primary endpoint) was estimated by the Kaplan-Meier method. RESULTS: A lower restenosis risk was observed for the AMG0102 group, but it was not statistically significant (stratified log-rank test P = 0.250, hazard ratio [HR] 0.774; 95% confidence interval [CI]: 0.500-1.198). The median duration of primary patency was 245 days and 172 days in the AMG0102 and control groups, respectively. After stratification based on the status of diabetes complications, the HR was 0.666 (95% CI: 0.366-1.212; P = 0.183) and the median duration of primary patency was prolonged by 108 days in the AMG0102 group with diabetes complications (245 days) compared with the control group (137 days). Adverse event (AE) incidence up to 36 postoperative weeks did not differ between groups. Four device failures occurred in 3 patients (AMG0102 group), but none resulted in AEs. CONCLUSION: Further modifications to enhance NF-κB decoy ODN uptake and efficacy are necessary to show its clinical utility for AVF stenosis in chronic HD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fukasawa M, Isobe M, Nanto S, et al. NF-κB Decoy Oligodeoxynucleotide-Coated Balloon Catheter for Arteriovenous Fistula in Hemodialysis. Kidney Int Rep. 2018. PMID: 30596176. doi:10.1016/j.ekir.2018.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。